We are live on
!
Find out more
BFO
Boston Family Office Portfolio holdings
AUM
$1.5B
1-Year Est. Return
11.68%
This Fund
S&P 500
This Quarter
Est. Return
+1.58%
1 Year Est. Return
+11.68%
3 Year Est. Return
+44.44%
5 Year Est. Return
+55.04%
10 Year Est. Return
+251.5%
AUM
$805M
AUM Growth
+$2.82M
(+0.35%)
Cap. Flow
-$5.52M
Cap. Flow
% of AUM
-0.69%
Top 10 Holdings %
Top 10 Hldgs %
21.48%
Holding
266
New
7
Increased
69
Reduced
92
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$1.49M |
| 2 |
JAH
JARDEN CORPORATION
JAH
|
+$861K |
| 3 |
AGN
Allergan plc
AGN
|
+$842K |
| 4 |
Labcorp
LH
|
+$776K |
| 5 |
Ecolab
ECL
|
+$712K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.98M |
| 2 |
AGN
Allergan Inc
AGN
|
+$1.74M |
| 3 |
Gilead Sciences
GILD
|
+$1.33M |
| 4 |
TFM
THE FRESH MARKET, INC COM STK
TFM
|
+$1.26M |
| 5 |
CELG
Celgene Corp
CELG
|
+$1.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.99% |
| 2 | Industrials | 14.98% |
| 3 | Technology | 12.91% |
| 4 | Consumer Staples | 10.2% |
| 5 | Financials | 6.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard FTSE Emerging Markets ETF
VWO
$117B
| $22.1M | 2.75% |
541,519
-14,080
| -3% | -$573K |
|
2
State Street SPDR S&P 500 ETF Trust
SPY
$771B
| $18.9M | 2.35% |
91,579
+1,043
| +1% | +$215K |
|
|
3
Gilead Sciences
GILD
$165B
| $18.4M | 2.29% |
187,945
-13,083
| -7% | -$1.33M |
|
4
Johnson & Johnson
JNJ
$640B
| $18.4M | 2.29% |
183,039
+10
| +0% | +$1.02K |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $18.2M | 2.25% |
157,512
-10,198
| -6% | -$1.22M |
|
|
SRCL
6
DELISTED
Stericycle Inc
SRCL
| $18M | 2.24% |
128,353
-432
| -0.3% | -$58.3K |
|
7
ExxonMobil
XOM
$650B
| $15.8M | 1.96% |
185,335
-974
| -0.5% | -$86.4K |
|
8
Apple
AAPL
$4.97T
| $14.9M | 1.85% |
479,072
-5,900
| -1% | -$178K |
|
|
ANSS
9
DELISTED
Ansys
ANSS
| $14.9M | 1.85% |
168,621
+699
| +0.4% | +$59.1K |
|
10
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$26.4B
| $13.4M | 1.66% |
48,263
-530
| -1% | -$143K |
|
11
General Mills
GIS
$20.2B
| $12.9M | 1.6% |
228,291
| – | – |
|
12
Procter & Gamble
PG
$340B
| $12.6M | 1.56% |
153,189
-1,565
| -1% | -$135K |
|
13
Middleby
MIDD
$6.01B
| $12.4M | 1.54% |
120,511
+1,606
| +1% | +$163K |
|
14
Union Pacific
UNP
$174B
| $12.2M | 1.52% |
112,804
+1,433
| +1% | +$168K |
|
15
Oracle
ORCL
$339B
| $11.7M | 1.45% |
271,331
-750
| -0.3% | -$32.5K |
|
16
iShares Core S&P Small-Cap ETF
IJR
$109B
| $11.2M | 1.38% |
188,990
-570
| -0.3% | -$32.7K |
|
17
Rockwell Automation
ROK
$51.1B
| $10.9M | 1.36% |
94,225
-45
| -0% | -$5.06K |
|
|
MRSH
18
Marsh
MRSH
$94.3B
| $10.6M | 1.32% |
189,843
+5,291
| +3% | +$298K |
|
19
SLB Ltd
SLB
$72.7B
| $10.2M | 1.26% |
121,963
+939
| +0.8% | +$78.2K |
|
20
Berkshire Hathaway Class B
BRK.B
$1.1T
| $9.9M | 1.23% |
68,632
-542
| -0.8% | -$79.7K |
|
21
American Tower
AMT
$83.5B
| $9.75M | 1.21% |
103,599
+3,162
| +3% | +$307K |
|
22
RTX Corp
RTX
$290B
| $9.09M | 1.13% |
123,225
+95
| +0.1% | +$7.09K |
|
23
PepsiCo
PEP
$196B
| $8.81M | 1.09% |
92,169
-50
| -0.1% | -$4.84K |
|
24
AptarGroup
ATR
$8.69B
| $8.72M | 1.08% |
137,324
-8,972
| -6% | -$577K |
|
25
GE Aerospace
GE
$364B
| $8.63M | 1.07% |
72,536
-101
| -0.1% | -$12K |
|
Similar funds
CP
JFGLC
AAM
TP
SCM
FMI
NSGL
RCW
Boston Family Office's Q1 2015 Portfolio in Review
As of Q1 2015, Boston Family Office held 266 positions worth $805M, up 0.35% from $803M the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Boston Family Office's Q1 2015 filing shows 7 new, 69 increased, 92 reduced and 7 closed positions. Its largest new stake was Medtronic: 19,713 shares worth $1.54M. The largest sale was COVIDIEN PLC COM SHS NEW (IRELAND), an estimated $1.98M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, down from 18% a quarter earlier, followed by Industrials and Technology.
- Boston Family Office's largest Q1 2015 buy was Medtronic: 19,713 shares worth $1.54M.
- Boston Family Office added most to Allergan plc in Q1 2015, an estimated $842K increase.
- Boston Family Office's biggest Q1 2015 reduction was Gilead Sciences, cutting an estimated $1.33M.
- Boston Family Office fully exited COVIDIEN PLC COM SHS NEW (IRELAND) in Q1 2015, selling an estimated $1.98M.
- Boston Family Office's ten largest holdings make up 21% of its $805M portfolio in Q1 2015.
- Boston Family Office opened 7 new positions and closed 7 in Q1 2015.
- Boston Family Office's portfolio value rose 0.35% quarter-over-quarter to $805M.
Based on Boston Family Office's 13F filing for Q1 2015, filed 11 May 2015.